JNJNYSE

JOHNSON & JOHNSON

Pharmaceutical Preparations · NJ · CIK 200406

Johnson & Johnson researches, manufactures, and sells a broad range of healthcare products

🔥 High media attention

+ Watch View on EDGAR ↗

$579.83B

Market cap

$258.51

Last close

+1.5%

+11.8%

8.6M

Volume

Price · last 39 sessions+15.3%

May 4L $221.32 · H $258.51Jun 29

260

Total filings

Jun 25, 2026

Last filing

01/03

Fiscal year end

All 8-K · 99 425 · 58 10-Q · 25 DEFA14A · 20 11-K · 19 SC 13G · 13 10-K · 9 DEF 14A · 9

425425Aug 23, 2023 425425Aug 21, 2023 425425Aug 18, 2023 425425Aug 17, 2023 425425Aug 17, 2023 425425

Similar companies

Comparable business profile · signals at a glance

ABBVAbbVie Inc.🔥$402.4B+0.4%JCIJohnson Controls International plc🔥$88.4B+1.5%ABTABBOTT LABORATORIES🔥$153.6B-1.5%SYKSTRYKER CORP🔥$119.7B-0.7%ENOV

Insider Activity

In the 90 days to Feb 27, 2026: 7 sold $80.5M.

Date	Insider	Action	Shares	Price	Value
Feb 27, 2026	Decker Robert JVP Corporate Controller	Sell	4,075	$247.87	$1.0M
Feb 20, 2026	Schmid TimothyEVP, WW Chair, MedTech	Sell	1,322	$245.66	$325K
Feb 18, 2026	Schmid TimothyEVP, WW Chair, MedTech	Sell	13,625	$244.20	$3.3M
Feb 18, 2026	Schmid TimothyEVP, WW Chair, MedTech	Sell	8,998	$244.53	$2.2M
Feb 17, 2026	Wolk Joseph JExec VP, CFO	Sell	33,386	$242.75	$8.1M
Feb 17, 2026	Reed John CEVP, Innovative Medicine, R&D	Sell	29,927	$243.00	$7.3M
Feb 17, 2026	Wolk Joseph JExec VP, CFO	Sell	24,961	$242.68	$6.1M
Feb 17, 2026	Reed John CEVP, Innovative Medicine, R&D	Sell	21,721	$243.00	$5.3M
Feb 17, 2026	Swanson James D.EVP, CIO	Sell	20,521	$242.70	$5.0M
Feb 17, 2026	Wolk Joseph JExec VP, CFO	Sell	19,241	$242.99	$4.7M
Feb 17, 2026	Wolk Joseph JExec VP, CFO	Sell	12,066	$242.87	$2.9M
Feb 17, 2026	Broadhurst VanessaEVP, Global Corp Affairs	Sell	6,197	$243.39	$1.5M
Feb 17, 2026	Reed John CEVP, Innovative Medicine, R&D	Sell	2,283	$243.00	$555K
Feb 13, 2026	Swanson James D.EVP, CIO	Sell	22,191	$243.71	$5.4M
Feb 13, 2026	Swanson James D.EVP, CIO	Sell	19,368	$243.76	$4.7M
Jan 26, 2026	Duato JoaquinCEO and Chairman of the Board	Sell	51,218	$220.99	$11.3M
Jan 26, 2026	Duato JoaquinCEO and Chairman of the Board	Sell	48,782	$221.48	$10.8M
Nov 26, 2025	Morikis John GDirector	Buy	1,250	$206.15	$258K
Oct 17, 2025	Reed John CEVP, Innovative Medicine, R&D	Sell	21,721	$192.71	$4.2M

Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.

What Changed

Risk factors · Feb 13, 2025 → Feb 11, 2026

12 added · 3 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.

Newly disclosed

Risks related to the planned separation of our Orthopaedics business The planned separation of the Company's Orthopaedics business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results In October 2025, the Company announced its intention to separate the Company's Orthopaedics business.
Completion of the planned separation will be subject to the satisfaction of certain conditions, including, among others, consultations with works councils and other employee representative bodies, as may be required, final approval of the Company's Board of Directors, and receipt of other regulatory approvals.
Unanticipated developments could delay, prevent or otherwise adversely affect the planned separation, including but not limited to disruptions in general or financial market conditions or potential problems or delays in obtaining various regulatory approvals or clearances.
In addition, the Company may be unable to achieve some of the strategic and financial benefits that it expects to achieve from the planned separation of the Company's Orthopaedics business The Company will incur significant expenses in connection with the planned separation.
Following the planned separation, the price of shares of the Company's common stock may fluctuate significantly The Company cannot predict the effect of the planned separation on the trading price of shares of its common stock, and market value of shares of its common stock may be less than, equal to or greater than the market value of shares of its common stock prior to the planned separation.
Changes in tax laws or regulations in the U.S. and around the world, including global minimum taxes could negatively impact the Company’s effective tax rate and results of operations.
In addition, the Company may not be able to achieve the full strategic and financial benefits that are expected to result from the planned separation.
There can be no assurance regarding the ultimate timing of the planned separation or that such separation will be completed.
The anticipated benefits of the planned separation are based on a number of assumptions, some of which may prove incorrect.
In addition, the price of the Company's common stock may be more volatile around the time of the planned separation.
The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement.
The costs to complete the planned separation will be significant.

No longer disclosed

Changes in tax laws or regulations around the world, including in the U.S. and as led by the Organization for Economic Cooperation and Development, such as the enactment by certain EU and non-EU countries, and the anticipated enactment by additional countries, of a global minimum tax, could negatively impact the Company’s effective tax rate and results of operations.
In addition, the U.S. government recently announced tariffs on products manufactured in several jurisdictions, including China, Mexico and Canada, and has 14 made announcements regarding the potential imposition of tariffs on other jurisdictions.
Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.

JOHNSON & JOHNSON

Similar companies

In the News

Insider Activity

What Changed